Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Hospitals warn Central Government Health Scheme reimbursement cap may hurt cancer treatment
A major private hospital group warns of a crisis for advanced cancer patients under the Central Government Health Scheme. A reimbursement cap on life-saving immunotherapy drugs is creating financial strain for hospitals. This policy threatens patient access to essential treatments. The association has identified nine specific drugs that are now out of reach for many beneficiaries.
Amazon India Expands Health Coverage For 90,000 Delivery Associates
These benefits will be rolled out to associates across all last-mile programmes, Amazon said.
Starmer Countdown Begins? UK Health Innovation Minister Quits Amid Calls For PM To Step Down
File image of UK Prime Minister Keir Starmer
Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity
Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The campaign aimed to reframe obesity as a chronic disease. It featured various media without naming specific products. Lilly cited regulatory uncertainty and conflicting guidance. The regulator's advisory prohibited indirect promotion of medicines. This pause impacts a public health initiative.
FSSAI issues notice on date sugar claims to The Whole Truth on rival’s complaint
The Whole Truth has come under scrutiny for its 'no added sugar' claims using date sweeteners, prompted by a complaint from rival Paul & Mike. This case may set a precedent for how similar health-food claims are interpreted by regulatory bodies.
Hantavirus Scare: Fatal Obsession? How A Quest For Rare Species Led To 'Patient Zero's' Diagnosis
Health officials have rejected comparisons to COVID-19 and said that there is little risk to global public health from the Hantavirus.
Moderna Shares Jump 5%: Why Hantavirus Scare Is Booster Dose For Wall Street's Pharma Majors
Pharma and biotech stocks rallied after the WHO flagged a hantavirus outbreak linked to a cruise ship, reviving investor bets on vaccine makers and outbreak-response specialists despite officials assessing the public health risk as low.
Average state per capita income could approach high-income thresholds by 2046-47
Poonam Gupta, Deputy Governor, Reserve Bank of India, has noted in a speech that India has attained a virtuous cycle of accelerated growth and macroeconomic stability. Macroeconomic stability is reflected in sustainable and resilient outcomes across inflation, the current account balance, fiscal position, debt quality, and financial sector health, among others. Key macroeconomic outcomes, especially growth (overall and sectoral) and inflation, are broadly less volatile and move within a narrower, more predictable range.
Manipal Health acquires land, hospital in Mumbai’s Andheri for Rs 495 crore
Manipal Health Enterprises has made headlines by purchasing a hospital site in Andheri, Mumbai for Rs 495 crore. This acquisition is a slice of a broader Rs 908 crore deal, signaling a robust appetite for healthcare real estate among investors in major Indian cities.
Manipal Health buys Mumbai hospital asset for ₹495 crore in Andheri
Manipal Health Enterprises buys Andheri hospital asset in Mumbai for ₹495 crore from Khubchandani entities, deal registered May 6 2026, highlighting demand for healthcare real estate
Accendra Health stock soars nearly 10% on first quarter earnings beat - Investing.com India
Accendra Health stock soars nearly 10% on first quarter earnings beatInvesting.com India
Biocon arm gets Health Canada nod for fungal infection treatment injection
Biocon Pharma Ltd has secured Health Canada approval for its micafungin for injection. This medication targets serious fungal infections in adults and children. It will be used for conditions like candidemia and esophageal candidiasis. The approval also covers prophylaxis in stem cell transplant patients. This marks a significant addition to Biocon's product offerings.